Stemline Therapeutics Inc (STML) Return on Equity ROE from the first quarter 2020 to first quarter 2019 and annually, average high and low, overall ranking from Mar 31 2020 to Mar 31 2019 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Stemline Therapeutics Inc  (STML)

Stemline Therapeutics Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Stemline Therapeutics Inc in the first quarter 2020?
Stemline Therapeutics Inc recorded a cumulative net loss of $-71 million during 12 months ending in the first quarter 2020, resulting in a negative return on equity (ROE) of -48.14%.

Within the Major Pharmaceutical Preparations industry 143 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2019 from 0 to 3319.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter
Y / Y Equity Change 35.59 % 287.7 % 176.11 % 23.89 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -71 -77 -86 -92 -94
Return On Equity (TTM) -48.14 % -56 % -80.29 % -116.58 % -127.05 %
STML's Total Ranking # 3319 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 148 164 175 101 109
Seq. Equity Change -9.76 % -6.74 % 74.06 % -7.44 % 158.03 %
Seq. Net Income Change - - - - -

Back to STML Management Effectiveness >> STML's 5 Years Annual ROE >> Compare STML ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 144
Sector # 363
Overall # 3319

Return On Equity Statistics
High Average Low
-36.65 %
-72.71 %
-130.93 %
(Sep 30 2015)   (Mar 31 2019)





STML Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 164 42 47 58 88
Y / Y Equity Change 287.7 % -10.34 % -18.45 % -34.49 % 59.01 %
Net Income in Millions -77 -85 -68 -38 -37
Y / Y Net Income Change - - - - -
Return On Equity -46.95 % -201.47 % -144.1 % -66.36 % -42.27 %

Back to STML Management Effectiveness >> STML's 5 Years Annual ROE >> Compare STML ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
STML's' Return on Equity at Yahoo Finance
STML's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for STML's Competitors
Subscribers only: Roe for Stemline Therapeutics Inc's Suppliers
Subscribers only: Return On Equity for STML's Customers




Companies with similar Return On Equity at Mar 31 2020, within Healthcare Sector ROE

Date modified: 2026-09-08T15:09:56+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.